Acetazolamide for the treatment of idiopathic intracranial hypertension

References

• Millichap JG, Millichap JJ. Mechanism of action of acetazolamide and idiopathic intracranial hypertension. Front Neurol 2015;6:1
   Google Scholar
• Howell NA, Maher J, Fasano A. Acetazolamide-induced myokymia. Parkinsonism Relat Disord 2015;21:542-3
   Google Scholar
• Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014;311:1641-51
   PubMed Web of Science ®Google Scholar
• Masri A, Jaafar A, Noman R, et al. Intracranial Hypertension in Children: Etiologies, Clinical Features, and Outcome. J Child Neurol 2015. [Epub ahead of print]
   Google Scholar
• Almarzouqi SJ, Morgan ML, Lee AG. Idiopathic intracranial hypertension in the Middle East: A growing concern. Saudi J Ophthalmol 2015;29:26-31
   Google Scholar
• Morgan WH, Balaratnasingam C, Lind CR, et al. Cerebrospinal fluid pressure and the eye. Br J Ophthalmol 2015; Epub ahead of print
   Google Scholar
• Baykan B, Ekizoğlu E, Altıokka Uzun G. An update on the pathophysiology of idiopathic intracranial hypertension alias pseudotumor cerebri. Agri 2015;27:63-72
   Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms ? Chem Rev 2012;112:4421-68
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008;7:168-81
   PubMed Web of Science ®Google Scholar
• Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review. 2008;Expert Opin Ther Pat 2012;22:903-15
   Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opinion on Therapeutic Patents 2006;16:1627-64
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnologic use for CO2 capture. J Enzyme Inhib Med Chem 2013;28:229-30
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Rev Drug Discov 2011;10:767-77
   PubMed Web of Science ®Google Scholar
• Liu F, Martin-Mingot A, Lecornué F, et al. Carbonic Anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry. J Enzyme Inhib Med Chem 2012;27:886-91
   PubMed Web of Science ®Google Scholar
• Cavdar H, Ekinci D, Talaz O, et al. α-Carbonic anhydrases are sulfatases with cyclic diol monosulfate esters. J Enzyme Inhib Med Chem 2012;27:148-54
   PubMed Web of Science ®Google Scholar
• Kazancıoğlu EA, Güney M, Sentürk M, Supuran CT. Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity. J Enzyme Inhib Med Chem 2012;27:880-5
   PubMed Web of Science ®Google Scholar
• Alp C, Ozsoy S, Alp NA, et al. Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI. J Enzyme Inhib Med Chem 2012;27:818-24
   PubMed Web of Science ®Google Scholar
• Carta F, Scozzafava A, Supuran CT. Sulfonamides (RSO2NH2): a patent review 2008-2012. Expert Opin Ther Pat 2012;22:747-58
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008 - 2012). Expert Opin Ther Pat 2013;23:203-13
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Pat 2012;22:79-88
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138-47
   PubMed Web of Science ®Google Scholar
• Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: A patent review. Expert Opin Ther Pat 2013;23:705-16
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin Ther Pat 2013;23:737-49
   PubMed Web of Science ®Google Scholar
• Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511-22
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: A patent and literature review (2005-2013). Expert Opin Ther Pat 2013;23:681-91
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11-15
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity Carbonic Anhydrase Inhibitors: A Literature and Patent review. Expert Opin Ther Pat 2013;23:725-35
   PubMed Web of Science ®Google Scholar
• Thiry A, Dognè JM, Masereel B, Supuran CT. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 2007;7:855-64
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-306
   PubMed Web of Science ®Google Scholar
• Bonneau A, Maresca A, Winum JY, Supuran CT. Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2013;28:397-401
   PubMed Web of Science ®Google Scholar
• Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;28:407-11
   PubMed Web of Science ®Google Scholar
• Halmi P, Parkkila S, Honkaniemi J. Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus. Neurochem Int 2006;48:24-30
   PubMed Web of Science ®Google Scholar
• Milhorat TH, Hammocck MK. Cerebrospinal fluid as a reflection of internal milieu of brain. Neurobiology of Cerebrospinal Fluid; Plenum Press; New-York: 1983. pp 1-23
   Google Scholar
• Brown PD, Davies SL, Speake T, Millar ID. Molecular mechanisms of cerebrospinal fluid production. Neuroscience 2004;129:957-70
   PubMed Web of Science ®Google Scholar
• Masuzawa T, Sato F. The enzyme histochemistry of the choroid plexus. Brain 1983;106(Pt 1):55-99
   PubMed Web of Science ®Google Scholar
• Davson H, Luck CP. The effect of acetazolamide on the chemical composition of the aqueous humour and cerebrospinal fluid of some mammalian species and on the rate of turnover of 24Na in these fluids. J Physiol 1957;137:279-93
   PubMedGoogle Scholar
• Vogh BP, Godman DR, Maren TH. Effect of AlCl3 and other acids on cerebrospinal fluid production: a correction. J Pharmacol Exp Ther 1987;243:35-9
   Google Scholar
• Swenson ER. A comparative approach to carbonic anhydrase: the work of Thomas H. Maren. Comp Biochem Physiol 2003;136:229-41
   Google Scholar
• Cowan F, Whitelaw A. Acute effects of acetazolamide on cerebral blood flow velocity and pCO2 in the newborn infant. Acta Paediatr Scand 1991;80:22-7
   Google Scholar
• Smith QR, Johanson CE. Chloride efflux from isolated choroid plexus. Brain Res 1991;562:306-10
   Google Scholar
• Maren TH. The kinetics of HCO3- synthesis related to fluid secretion, pH control, and CO2 elimination. Annu Rev Physiol 1988;50:695-717
   PubMed Web of Science ®Google Scholar
• Swenson ER. Safety of carbonic anhydrase inhibitors. Expert Opin Drug Saf 2014;13:459-72
   PubMed Web of Science ®Google Scholar
• Supuran CT, Clare BW. Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties. Eur J Med Chem 1999;34:41-50
   Web of Science ®Google Scholar
• Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001-10
   Web of Science ®Google Scholar
• Borras J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors. Part 73. Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring ? Bioorg Med Chem 1999;7:2397-406
   PubMed Web of Science ®Google Scholar
• Supuran CT, Ilies MA, Scozzafava A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur J Med Chem 1998;33:739-52
   Web of Science ®Google Scholar
• Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: Clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024-31
   PubMed Web of Science ®Google Scholar
• Bozdag M, Ferraroni M, Carta F, et al. Structural insights on carbonic anhydrase inhibitory action, isoform selectivity and potency of sulfonamides and coumarins incorporating arylsulfonylureido groups. J Med Chem 2014;57:9152-67
   PubMed Web of Science ®Google Scholar